Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 326 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CAP-IT Clear all
Completed Not applicable Interventional

A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections.

NCT06665126
View directory record Official record
Conditions
Bacterial Vaginosis, Yeast Infection
Interventions
Prebiotic + Probiotic Supplement, Active Placebo Supplement, Excipient Placebo Supplement
Dietary Supplement
Lead sponsor
Happy V
Industry
Eligibility
25 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

NCT02853435
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Nov 4, 2026, 2:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

NCT05735249
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
ARN-75039 oral capsules, Placebo
Drug
Lead sponsor
Arisan Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Nov 4, 2026, 2:56 AM EST
Completed Phase 2 Interventional

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

NCT00797953
View directory record Official record
Conditions
Angina Pectoris
Interventions
T89
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Nov 4, 2026, 2:56 AM EST
Completed Phase 2 Interventional Results available

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

NCT01844765
View directory record Official record
Conditions
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
10
States / cities
Loma Linda, California • Palo Alto, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Nov 4, 2026, 2:56 AM EST
Recruiting Phase 2 Interventional

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

NCT05289687
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia
Interventions
Daratumumab / Hyaluronidase Injection
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Completed Not applicable Interventional Results available

High Pain Intervention in Cesarean Sections

NCT01298778
View directory record Official record
Conditions
Other Chronic Postoperative Pain
Interventions
Duramorph 150, Acetaminophen, Duramorph 300
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Nov 4, 2026, 2:56 AM EST
Recruiting Phase 3 Interventional

Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

NCT05206955
View directory record Official record
Conditions
Fontan Palliation
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of a Cepham Supplement on Hot Flashes and Menopausal Symptoms in Postmenopausal Women

NCT06939868
View directory record Official record
Conditions
D008593
Interventions
Shatavari Root Extract, oral capsule
Dietary Supplement
Lead sponsor
Jacksonville University
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Nov 4, 2026, 2:56 AM EST
Completed Phase 2 Interventional Results available

ALS Reversals - Lunasin Regimen

NCT02709330
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Lunasin Regimen, Historical control
Drug · Other
Lead sponsor
Richard Bedlack, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Nov 4, 2026, 2:56 AM EST
Recruiting Not applicable Interventional

Assessment of a Physio-neuro Platform (SynPhNe) for Home-based Retraining of Hand Function in Stroke Survivors

NCT02896348
View directory record Official record
Conditions
Stroke, Hemiparesis
Interventions
SynPhNe platform, Conventional therapy
Device · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Tyrosol and Creatine on Exercise Performance and Cognition in Healthy Adults

NCT07756658
View directory record Official record
Conditions
Tyrosol, Creatine, Endurance Performance, Cognition, Mood
Interventions
Tyrosol, Creatine Monohydrate, Resistant Dextrin
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Centella Asiatica in Older Adults

NCT06472791
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Centella Asiatica, Placebo Comparator
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
50 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Terminated Phase 2 Interventional Results available

Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis

NCT04252625
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Q-Urol, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Recruiting Phase 2 Interventional

RESvEraTrol in Parkinson's Disease (RESET)

NCT07592767
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Trans-Resveratrol
Drug
Lead sponsor
Georgetown University
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Completed Phase 2 Interventional Results available

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

NCT03030248
View directory record Official record
Conditions
Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Terminated Phase 1 Interventional

A Study of MRx-4DP0004 in Asthma

NCT03851250
View directory record Official record
Conditions
Asthma
Interventions
MRx-4DP0004, Placebo
Drug
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Nov 4, 2026, 2:56 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Design Factors for Evaluating Child Resistant Packaging

NCT03925623
View directory record Official record
Conditions
Unintentional Injury
Interventions
Novel approaches for the design of child resistant closures
Other
Lead sponsor
Michigan State University
Other
Eligibility
42 Months to 54 Months
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
East Lansing, Michigan • Haslett, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Nov 4, 2026, 2:56 AM EST
Terminated Phase 3 Interventional Results available

Effectiveness of Zonisamide in Alcohol Dependent Veterans

NCT02368431
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Nov 4, 2026, 2:56 AM EST
Completed Phase 3 Interventional

Function of Tamsulosin in Older Males Undergoing Surgery With Indwelling Catheter

NCT06257576
View directory record Official record
Conditions
Postoperative Urinary Tract Infection
Interventions
Tamsulosin, Control Group
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
50 Years and older · Male only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Active, not recruiting Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

NCT05052996
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ISL, LEN, B/F/TAF, ISL/LEN FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Beverly Hills, California • Los Angeles, California • Newport Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Terminated Not applicable Interventional

How Gas-Filled Intragastric Balloons or Endoscopic Sleeve Gastroplasty Affect Hunger, Hunger Hormones, and Gastric Emptying Compared to Meal Replacements

NCT04306445
View directory record Official record
Conditions
Obesity
Interventions
GF-IGB: Obalon Balloon, Medically Supervised Meal Replacement Program: My New Weigh, Endoscopic sleeve gastroplasty: (ESG)
Device · Dietary Supplement · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 4, 2026, 2:56 AM EST
Terminated Not applicable Interventional

CuraLin Herbal Supplement for Type 2 Diabetes

NCT05267925
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
CuraLin
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Nov 4, 2026, 2:56 AM EST